Table 3.

Cox proportional hazard ratios and 95% confidence intervals for time from diagnosis to death, all adenocarcinomas and moderately to well-differentiated adenocarcinoma, SEER Residual Tissue Repository TMA, by mucin expression status

HistologyMucinNoExpression statusMedian survival *Unadjusted model HR (95% CI)Adjusted model HR (95% CI)
All ACsAll three mucins combined81Positive5.01.6(1.2-2.3)1.5(1.1-2.2)
73Negative11.01.0Reference1.0Reference
(96% of tumors in the TMA)MUC1139Positive20.02.4(1.3-4.4)1.6(0.9-3.0)
15Negative6.01.0Reference1.0Reference
MUC289Positive11.01.5(1.1-2.1)1.5(1.0-2.1)
65Negative5.01.0Reference1.0Reference
MUC5AC99Positive10.01.3(0.9-1.8)1.4(1.0-2.1)
55Negative5.01.0Reference1.0Reference
Well- and moderately differentiated ductal ACAll three mucins combined68Positive5.01.8(1.2-2.6)1.8(1.2-2.6)
52Negative12.51.0Reference1.0Reference
(75% of tumors in the TMA)MUC1112Positive6.02.7(1.2-6.2)2.5(1.1-5.7)
8Negative25.01.0Reference1.0Reference
MUC275Positive5.01.6(1.1-2.3)1.6(1.1-2.4)
45Negative13.01.0Reference1.0Reference
MUC5AC82Positive5.01.3(0.9-2.0)1.5(1.0-2.4)
38Negative12.01.0Reference1.0Reference
  • NOTE: Associations not shown for 24 poorly differentiated ductal AC, 7 neuroendocrine, and 10 specialized adenocarcinomas.

  • * Survival time in months from diagnosis to death.

  • Adjusted for gender, time period, age (<75 versus 75+ y), race (Asian versus non-Asian), stage (local and regional versus distant and unstaged), pancreatic versus metastatic tissue, and ever versus never surgical or radiation treatment for pancreatic cancer.